Can a simple arthritis drug prevent brain damage from cancer therapy?
NCT ID NCT04205838
First seen Feb 27, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This study tested whether anakinra, a drug that calms the immune system, could prevent severe brain side effects in people receiving CAR T-cell therapy for aggressive B-cell lymphoma. The trial included 23 patients whose lymphoma had returned or not responded to prior treatments. The study was stopped early, but researchers aimed to see if anakinra could safely reduce the risk of confusion, seizures, or other serious neurological problems after CAR T-cell therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UC Davis Comprehensive Cancer Center
Davis, California, 95817, United States
-
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095, United States
Conditions
Explore the condition pages connected to this study.